CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
With sorrow, CCTG would like to note the recent passing of Dr. David Osoba.
A look back at 2020, a pandemic year that saw tremendous achievements across the CCTG network
This past year has been one of constant challenge within our group, network, country, and the world. Yet despite the disruptions to our daily lives and work, this year has also been one of immense accomplishment.
PR21 A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has been centrally activated.
Holiday hours and days of operation for the CCTG central office, CCTG’s Tumour Tissue Data Repository and the Bay Area Research Logistics.
Everyone at CCTG would like to congratulate Dr Joseph Connors for his recent appointment to the Order of Canada, as one of 114 Canadian appointees “whose service has shaped our society; whose innovations ignite our imaginations; and whose compassion unites our communities.”
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.
As with most events in 2020 the 62nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in.
MAC21 (NCT02927249), A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, has closed to accrual after completion of target accrual.
